Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaPrecise Phase II Open Label Study of intralymphatic Diamyd (GAD65) in pre-type 1 diabetes
2022-002356-39Phase 2Active
- Sponsor
- Diamyd Medical
- Start
- Oct 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Diamyd in diabetes mellitus type 1 (T1D), sponsored by Diamyd Medical. Started Oct 2022; status: active.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2022-002356-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002356-39.